Fresenius Medical Care Reports Increased Q3 Results and Reaffirms FY25 Forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 04 2025
0mins
Source: NASDAQ.COM
Financial Performance: Fresenius Medical Care reported a 29% increase in net income to 275 million euros in Q3, with adjusted net income growing 36% to 322 million euros. Basic earnings per share rose to 0.94 euros from 0.73 euros.
Revenue Growth: The company's revenue for the third quarter increased by 3% to 4.89 billion euros, with an 8% rise at constant currency and a 10% organic growth across all operating segments.
Future Outlook: Fresenius Medical Care confirmed its fiscal 2025 outlook, expecting positive revenue growth at constant currency in the low-single digits and operating income growth in the high-teens to high-twenties percent range.
Cost Savings Program: The company anticipates full-year FME25+ savings to reach 1.05 billion euros by the end of 2027, with associated program costs estimated between 1 billion euros and 1.05 billion euros during the same period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FMS
Wall Street analysts forecast FMS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FMS is 25.00 USD with a low forecast of 22.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
0 Buy
1 Hold
1 Sell
Moderate Sell
Current: 22.190
Low
22.00
Averages
25.00
High
28.00
Current: 22.190
Low
22.00
Averages
25.00
High
28.00
About FMS
Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Glaukos Corp (GKOS) Projects FY25 Sales of $507 Million, Shares Drop 12.1%
- Glaukos Sales Projection: Glaukos Corp anticipates FY25 sales of $507 million, yet its shares fell 12.1% in pre-market trading, indicating market concerns about its growth outlook despite the positive sales forecast.
- Briacell's Sharp Decline: Briacell Therapeutics' announcement of a $30 million public offering led to a staggering 53.1% drop in its stock price during pre-market trading, reflecting investor apprehension regarding the financing strategy.
- Trip.com Investigation Impact: Trip.com Group confirmed it is under investigation by China's SAMR for potential anti-monopoly violations, resulting in a 9.3% decline in its pre-market stock price, which may adversely affect its market performance and investor confidence.
- Pearson Trading Update: Pearson PLC's trading update for 2025 caused its shares to drop 7.2% in pre-market trading, indicating a cautious market sentiment regarding its future performance.
Continue Reading
Focus Graphite Develops Low-Cost AI Technology to Enhance Lac Tetepisca Project Economics
- Technological Innovation: Focus Graphite has successfully developed and validated a low-cost AI-enabled in situ graphite flake size characterization technology, directly integrated into the geometallurgical model of the Lac Tetepisca Project, thereby enhancing resource valuation accuracy and mining planning efficiency.
- Economic Benefits: Preliminary results indicate an inverse relationship between graphite grade and flake size, supporting the potential for a lower cut-off grade, which is expected to positively impact project economics, particularly in the upcoming mineral resource estimate.
- Sample Processing Progress: Approximately 300 samples are currently being processed to support the mineral resource estimate update anticipated in Q1 2026, ensuring the effectiveness and reliability of the new technology.
- Sustainability Strategy: The application of this technology not only enhances selective mining but also complements Focus's ESG initiatives by promoting low-emission, chemical-free purification technologies, ensuring a sustainable supply chain from mine to market.
Continue Reading